One of the most fundamental clinical distinctions between breast cancer subtypes is whether the tumor responds to growth signaling through the hormonal (ER/PR) or HER2 receptors, as these tumors can be targeted with modern anti-hormonal or anti-HER2 therapy, respectively. Here, ERBB2 is linked to breast carcinoma.